Vitrafy Life Sciences Ltd.

As of June 30, 2026, Vitrafy Life Sciences Ltd. carries a market capitalization of 226.92M, placing it among publicly traded companies globally. Its enterprise value stands at 186.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vitrafy Life Sciences Ltd.'s next confirmed earnings release is scheduled for February 11, 2027.

As of June 30, 2026, Vitrafy Life Sciences Ltd. has 75.39M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1,145.82, and the price-to-book ratio stands at 5.52.

These figures are as of June 30, 2026. The EV/Sales ratio of 1,102.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 186.05M versus a market cap of 226.92M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Vitrafy Life Sciences Ltd. maintains a current ratio of 23.77, meaning it holds 23.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.74, indicating moderate leverage, while an interest coverage ratio of -7,691.15 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Vitrafy Life Sciences Ltd. posted a negative return on equity (ROE) of -46.29, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -43.09, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Vitrafy Life Sciences Ltd.'s stock has gained approximately 119.92% over the past 52 weeks. The 50-day moving average sits at 3.55, while the 200-day moving average is 2.62.

Over the twelve months ended June 30, 2026, Vitrafy Life Sciences Ltd. generated 168,726.00 in revenue and converted that into -16.17M in net income, yielding earnings per share of -0.25. EBITDA reached -20.31M, while operating income came in at -20.44M.

As of June 30, 2026, Vitrafy Life Sciences Ltd. holds 41.17M in cash and equivalents against 302,574.00 in total debt, resulting in a net debt position of -26.10M. Total book value stands at 41.11M, with working capital of 40.59M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -12,112.46 and net profit margin of -9,584.18 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -12.29, meaning Vitrafy Life Sciences Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Vitrafy Life Sciences Ltd. has an Altman Z-Score of 61.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.